Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway

<table>Histopathological improvement of LIRA-treated diabetic myocardium. The normal myocardium, diabetic myocardium and LIRA or ISN treated DCM myocardium were stained with HE staining (200x magnification). Representative samples of normal rats (a), diabetic cardiomyopathy rats (b), INS treated DCM rats (c), and LIRA treated DCM rats ((d) to (f)) were shown in the figure. Arrows indicate regions with ischemic myocyte degeneration in the subendocardial, subepicardial region and papillary muscles of the myocardium. Bar = 50 <i>μ</i>m.</table>

Journal of Diabetes Research

fig1

Figure 1

Figure 1: Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway 

Figure 1 | Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway 